Hinge Health Inc. $HNGE Shares Purchased by First Eagle Investment Management LLC

First Eagle Investment Management LLC raised its stake in shares of Hinge Health Inc. (NYSE:HNGE) by 167.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 221,751 shares of the company’s stock after buying an additional 138,751 shares during the period. First Eagle Investment Management LLC’s holdings in Hinge Health were worth $10,300,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Hinge Health by 110.5% during the 4th quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company’s stock valued at $121,027,000 after buying an additional 1,367,693 shares during the last quarter. BIT Capital GmbH boosted its holdings in shares of Hinge Health by 144.6% during the third quarter. BIT Capital GmbH now owns 1,849,524 shares of the company’s stock worth $90,775,000 after purchasing an additional 1,093,320 shares during the last quarter. Bamco Inc. NY acquired a new stake in shares of Hinge Health during the second quarter worth $48,943,000. Braidwell LP acquired a new stake in shares of Hinge Health during the third quarter worth $44,686,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Hinge Health during the second quarter worth $27,040,000.

Hinge Health Trading Up 0.8%

Shares of Hinge Health stock opened at $55.17 on Wednesday. Hinge Health Inc. has a twelve month low of $30.08 and a twelve month high of $62.18. The stock has a market capitalization of $4.35 billion and a P/E ratio of -4.47. The business’s fifty day moving average price is $43.58 and its 200 day moving average price is $44.12.

Hinge Health (NYSE:HNGE) last issued its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.33. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The firm had revenue of $182.31 million for the quarter. During the same quarter in the previous year, the business posted $1.30 EPS. Hinge Health’s revenue was up 47.2% compared to the same quarter last year. As a group, sell-side analysts predict that Hinge Health Inc. will post 0.78 EPS for the current year.

Insider Transactions at Hinge Health

In other Hinge Health news, CFO James Budge sold 11,006 shares of the firm’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $42.26, for a total value of $465,113.56. Following the transaction, the chief financial officer directly owned 401,427 shares of the company’s stock, valued at $16,964,305.02. This trade represents a 2.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Gabriel M.I. Mecklenburg sold 166,666 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $45.32, for a total value of $7,553,303.12. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 648,576 shares of company stock worth $30,122,850 over the last ninety days. 18.92% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on HNGE shares. Needham & Company LLC raised their price objective on Hinge Health from $59.00 to $63.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Freedom Capital upgraded Hinge Health to a “strong-buy” rating in a report on Thursday, January 22nd. Citizens Jmp raised their price objective on Hinge Health from $65.00 to $80.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Truist Financial set a $79.00 price objective on Hinge Health in a report on Wednesday, May 6th. Finally, Piper Sandler restated an “overweight” rating and set a $95.00 price objective on shares of Hinge Health in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $67.40.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.